ESA Use In Chronic Kidney Disease Will Get Second MedCAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare coverage of Amgen's Aranesp and other erythropoiesis-stimulating agents in chronic kidney disease is the topic for a meeting by the Medicare Evidence Development and Coverage Advisory Committee on Jan. 19.